Does Perseris Cause Weight Gain?
Perseris, an extended-release risperidone injection for schizophrenia, lists weight gain as a common side effect. Clinical trials showed 18-23% of patients gaining 7% or more body weight over 6 months, compared to 9% on placebo.[1][2] Post-marketing data confirms this risk, with average gains of 1-2 kg in the first year, often dose-dependent and more pronounced in early treatment.[3]
How Common Is Weight Gain on Perseris?
In pivotal trials (RISE and RISE-A), weight increased by at least 7% from baseline in:
- 23% of 2 mg monthly doses
- 18% of 3-4 mg monthly doses
- 9% placebo
Longer-term studies (up to 56 weeks) report mean gains of 2.1 kg overall, with higher rates in antipsychotic-naive patients.[2][4] Women and younger adults (<40) face elevated risk.
Why Does Perseris Lead to Weight Gain?
Risperidone, Perseris's active ingredient, blocks histamine and serotonin receptors, increasing appetite and altering metabolism. It also raises prolactin, linked to fat accumulation. Unlike oral risperidone, Perseris's steady subcutaneous release may sustain these effects without first-pass metabolism fluctuations.[1][5]
Compared to Other Antipsychotics
Perseris causes moderate weight gain, less than olanzapine (up to 4 kg mean) or clozapine, but more than aripiprazole or ziprasidone (often weight-neutral). In head-to-head data, risperidone trails second-generation atypicals like quetiapine in gain severity.[6]
| Drug | Mean Weight Gain (1 year) |
|------|---------------------------|
| Perseris (risperidone ER) | 1-2 kg [2] |
| Olanzapine | 3-5 kg [6] |
| Aripiprazole | 0-0.5 kg [6] |
| Placebo | 0.5 kg [2] |
Managing Weight Gain on Perseris
Monitor BMI monthly initially; lifestyle changes (diet, exercise) mitigate 50-70% of gains. Topiramate or metformin as adjuncts reduce gain by 1-3 kg in trials. Switching to lurasidone or brexpiprazole limits further increase.[3][7] FDA requires weight monitoring in labeling.
Who Is Most at Risk?
Patients with baseline obesity, diabetes family history, or first-episode psychosis gain more (up to 10% body weight). Adolescents and females show 1.5-2x higher incidence.[4][8]
[1]: Perseris Prescribing Information, FDA (indivior.com/perseris-pi.pdf)
[2]: Phase 3 RISE Study, J Clin Psychiatry (2018)
[3]: Postmarketing Surveillance, DrugSafety (2020)
[4]: Long-term Extension Data, Neuropsychopharmacology (2019)
[5]: Mechanism Review, Lancet Psychiatry (2017)
[6]: CATIE Trial Meta-Analysis, Am J Psychiatry (2009)
[7]: Adjunct Therapy RCT, Schizophr Res (2021)
[8]: Risk Factor Analysis, J Clin Psychopharmacol (2022)